At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 109 enrolled
Drug / intervention
rizatriptan +2 moredrug
Likely dose
rizatriptan 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Efficacy and Tolerability of Rizatriptan 10 mg for the Treatment of Acute Migraine in Sumatriptan Non-Responders
In Brief
A Phase 3 clinical trial evaluating rizatriptan, Comparator: Placebo, and 1 other intervention for Acute Migraine. Completed, enrolled 109 participants.
Detailed Summary
A study to provide evidence supporting the benefit of Rizatriptan in patients who have an inadequate response to sumatriptan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Migraine
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJun 2009
Primary CompletionJan 2010
TodayJul 2026
First PostedMay 7, 2009
Enrollment StartJun 10, 2009
Primary CompletionJan 12, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.2 years ago
Interventions
rizatriptandrug
Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
Comparator: Placebodrug
Placebo to Rizatriptan
Comparator: Sumatriptandrug
single dose of generic sumatriptan 100 mg at onset of migraine attack